Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 6, 2013, Pages 1167-1175

  Di Somma, Salvatore ^a   Magrini, Laura ^a   Travaglino, Francesco ^a   Lalle, Irene ^a   Fiotti, Nicola ^b   Cervellin, Grianfranco ^c   Avanzi, Gian Carlo ^d   Lupia, Enrico ^e   Maisel, Alan ^f   Hein, Frauke ^g   Wagner, Florian ^h   Lippi, Giuseppe ⁱ  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ADRENOMED AG   (Germany)

^h UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

ⁱ ACADEMIC HOSPITAL OF PARMA   (Italy)

Author keywords

Biomarkers; Emergency department; Infection; Procalcitonin; Sepsis

Indexed keywords

ADRENOMEDULLIN; BIOLOGICAL MARKER; COPEPTIN; INDUCIBLE PROTEIN 10; MATURE ADRENOMEDULLIN; MER RECEPTOR; NATRIURETIC FACTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PHOSPHOLIPASE A2 GROUP IV; PROCALCITONIN; PROTEIN; RECEPTOR; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ARTICLE; CRITICALLY ILL PATIENT; DEATH; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EMERGENCY WARD; ERYTHROCYTE; HUMAN; INFECTION; MONITORING; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RESUSCITATION; RISK; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADULT; BIOLOGICAL MARKERS; CALCITONIN; CHILD; COMMUNICABLE DISEASES; DISEASE MANAGEMENT; EMERGENCY MEDICINE; EMERGENCY SERVICE, HOSPITAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; PROTEIN PRECURSORS; SEPSIS;

EID: 84882428406     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0795     Document Type: Article

References (48)

1. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010;38:1045-53.
2. Adib-Conquy M, Cavaillon JM. Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 581 2007;58:3723-33.
3. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010;14:R15.
4. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth F R 1997;8:207-19.
5. Liu MS, Liu CH, Wu G, Zhou Y. Antisense inhibition of secretory and cytosolic phospholipase A2 reduces the mortality in rats with sepsis. Crit Care Med 2012;40:2132-40.
6. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 2011;66(Suppl 2):ii33-40.
7. Cervellin G, Pedrazzoni M, Passeri M. New polypeptide hormonal candidates encoded by the calcitonin gene. Rec Progr Med 1983;74:979-85.
8. Hausfater P, Brochet C, Freund Y, Charles V, Bernard M. Procalcitonin measurement in routine emergency medicine practice: comparison between two immunoassays. Clin Chem Lab Med 2010;48:501-4.
9. Bele N, Darmon M, Coquet I, Feugeas JP, Legriel S, Adaoui N, et al. Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. Infect Dis 2011;11:224-32.
10. Maisel A, Neath SX, Landsberg J, Mueller C, Nowak RM, Peacock WF, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Failure 2012;14:278-86.
11. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections. The ProHOSP Randomized Controlled Trial. J Am Med Assoc 2009;302:1059-66.
12. Lippi G, Meschi T, Cervellin G. Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneumonia: clinical evidence and perspectives. Eur J Intern Med 2011;22:460-5.
13. Cervellin G, Di Somma S. Neutrophil gelatinase-associated lipocalin (NGAL): the clinician's perspective. Clin Chem Lab Med 2012;50:1489-93.
14. Chelazzi C, Villa G, De Gaudio AR. Cardiorenal syndromes and sepsis. Int J Nephrol 2011;2011:652967.
15. Charles PE, Kus E, Aho S, Prin S, Doise JM, Olsson NO, et al. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis 2009;9:49-58.
16. Harbarth S, Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396-402.
17. Lippi G, Cervellin G. Estimation of glomerular filtration rate in acute kidney injury. Clin Chim Acta 2012;414C:34-5.
18. Lippi G, Plebani M. Neutrophil gelatinase-associated lipocalin (NGAL): the laboratory perspective. Clin Chem Lab Med 2012;50:1483-7.
19. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase- associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med 2012;50:1505-17.
20. Lentini P, De Cal M, Clementi A, D'Angelo A, Ronco C. Sepsis and AKI in ICU patients: the role of plasma biomarkers. Crit Care Res Pract 2012;2012:856401.
21. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, et al. The diagnostic accuracy of plasma neutrophil gelatinase-associated lipocalin in the prediction of acute kidney injury in emergency department patients with suspected sepsis. Ann Emerg Med 2010;56:52-9.
22. Magrini L, Travaglino F, Marino R, Ferri E, De Berardinis B, Cardelli P, et al. Procalcitonin variations after emergency department admission are highly predictive of hospital mortality in patients with acute infectious diseases. Eur Rev Med Pharmacol Sci 2013 (in press).
23. Lippi G, Cervellin G. Neutrophil gelatinase-associated lipocalin: a more specific assay is needed for diagnosing renal injury. Clin Chim Acta 2012;413:1160-1.
24. Lippi G, Cervellin G. The predictive value of plasma neutrophil gelatinase-associated lipocalin on cardiovascular death and all-cause mortality might be mediated by leukocytosis. J Am Coll Cardiol 2012;60:564-5.
25. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock:2008. Crit Care Med 2008;36:296-327.
26. Marshall JC, Reinhart K. Biomarkers of sepsis. Crit Care Med 2009;37:2290-8.
27. Travaglino F, De Berardinis B, Magrini L, Bongiovanni C, Candelli M, Silveri NG, et al. Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score. BMC Infect Dis 2012;12:184-92.
28. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009;60:193-206.
29. Lupia E, Goffi A, Bosco O, Montrucchio G. Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases. Mediat Inflamm 2012;2012:390892.
30. Zakynthinos SG, Papanikolaou S, Theodoridis T, Zakynthinos EG, Christopoulou-Kokkinou V, Katsaris G, et al. Sepsis severity is the major determinant of circulating thrombopoietin levels in septic patients. Crit Care Med 2004;32:1004-10.
31. Lupia E, Bosco O, Mariano F, Dondi AE, Goffi A, Spatola T, et al. Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activation. J Thromb Haemost 2009;7:1000-8.
32. Lupia E, Spatola T, Cuccurullo A, Bosco O, Mariano F, Pucci A, et al. Thrombopoietin modulates cardiac contractility in vitro and contributes to myocardial depressing activity of septic shock serum. Basic Res Cardiol 2010;105:609-20.
33. Rothlin CV, Lemke G. TAM receptor signaling and autoimmune disease. Curr Opin Immunol 2010;22:740-6.
34. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001;293:306-11.
35. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001;411:207-11.
36. Alciato F, Sainaghi PP, Sola D, Castello L, Avanzi GC. TNF-alpha, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages. J Leukocyte Biol 2010;87:869-75.
37. Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase C δ, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem 2011;286:33335-44.
38. Borgel D, Clauser S, Bornstain C, Bièche I, Bissery A, Remones V, et al. Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit Care Med 2006;34:219-22.
39. Müller B, Gencay MM, Gibot S, Stolz D, Hunziker L, Tamm M, et al. Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM)-1 in community-acquired pneumonia. Crit Care 2007;35:990-1.
40. Ekman C, Linder A, Akesson P, Dahlbäck B. Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes. Crit Care 2010;14:158-63.
41. Bełtowski J, Jamroz A. Adrenomedullin-what do we know 10 years since its discovery? Pol J Pharmacol 2004;56:5-27.
42. Meeran K, O'Shea D, Upton PD, Small CJ, Ghatei MA, Byfield PH. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 1997;82:95-100.
43. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76.
44. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocrinol Rev 2000;21:138-67.
45. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Comm 1993;192:553-60.
46. Wu R, Higuchi S, Dong W, Ji Y, Zhou M, Marini CP, et al. Reversing established sepsis in rats with human vasoactive hormone adrenomedullin and its binding protein. Mol Med 2009;15:28-33.
47. Guignant C, Voirin N, Venet F, Poitevin F, Malcus C, Bohé J, et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intens Care Med 2009;35:1859-67.
48. Lippi G, Teti L, Dipalo M, Cervellin G. Relationship between red blood cell distribution width and prognostic biomarkers in patients admitted to the emergency department with acute infections. Eur J Intern Med 2012 Sep. 24. [Epub ahead of print].